Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
lansoprazole, Quantity: 30 mg
Arrotex Pharmaceuticals Pty Ltd
Lansoprazole
Capsule
Excipient Ingredients: indigo carmine; Gelatin; hypromellose; macrogol 300; purified talc; maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; sucrose; carmoisine; colloidal anhydrous silica; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; Shellac; sulfuric acid
Oral
28 and 30
(S4) Prescription Only Medicine
Adults:. APO-LANSOPRAZOLE capsules are indicated for. - Healing and long-term management of reflux oesophagitis. . - Healing and long-term management for patients with duodenal ulcer.. - Healing of benign gastric ulcer. Patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - Patients with benign peptic lesions that do not respond to H2-receptor antagonists.. - Eradication of H. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - Relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . Paediatric and adolescent patients I to 17 years of age:. APO-LANSOPRAZOLE capsules are indicated for. - Treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - Healing of erosive oesophagitis.
Visual Identification: Purple cap/lavender body, self-locked hard gelatin capsules of size '1' imprinted 'L30' on both cap and body, containing white to off-white pellets; Container Type: Strip Pack; Container Material: Other composite material; Container Life Time: 18 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2010-02-12
APO-LANSOPRAZOLE CAPSULES 1 APO-LANSOPRAZOLE CAPSULES _Contains the active ingredient lansoprazole _ CONSUMER MEDICINE INFORMATION _FOR A COPY OF A LARGE PRINT LEAFLET, PH: 1800 195 055 _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about lansoprazole. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT THIS MEDICINE IS USED FOR The name of your medicine is APO- Lansoprazole. It contains the active ingredient lansoprazole. In adults it is used to treat: • reflux oesophagitis • peptic ulcers • Helicobacter pylori infection in patients with peptic ulcer or chronic gastritis • reflux-like and/or ulcer-like symptoms associated with acid- related dyspepsia In children aged 1-17 years of age it is used to treat: • gastro-oesophageal reflux disease, including all grades of oesophagitis • erosive oesophagitis Lansoprazole belongs to a group of medicines called proton pump inhibitors (PPIs). It works by decreasing the amount of acid the stomach makes, to give relief from excessive acid and allow healing to take place. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed this medicine for another reason. There is no evidence that this medicine is addictive. This medicine is available only with a doctor's prescription. BEFORE YOU TAKE THIS MEDICINE _WHEN YOU MUST NOT TAKE IT _ DO NOT TAKE THIS MEDICINE IF YOU HAVE ALLERGY TO: • lansoprazole or other proton pump inhibitors • any of the ingredients listed at the end of this leaflet Some of the symptoms of an allergic reaction may include: • shortness of breath, cough, wheezing or difficulty Read the complete document
1 AUSTRALIAN PRODUCT INFORMATION APO-LANSOPRAZOLE (LANSOPRAZOLE) CAPSULES 1 NAME OF THE MEDICINE Lansoprazole 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each APO-Lansoprazole enteric capsule contains enteric-coated delayed release pellets with 15 mg or 30 mg of lansoprazole. EXCIPIENTS WITH KNOWN EFFECT Contains sugars as sucrose. Contains sulfites. For the full list of excipients see section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM APO-LANSOPRAZOLE 15 MG ENTERIC CAPSULES: Yellow cap/yellow body, self-locked hard gelatin capsules of size ‘3’ imprinted with ‘L 15’ on both cap and body, containing white to off-white pellets. APO-LANSOPRAZOLE 30 MG ENTERIC CAPSULES: Purple cap/lavender body, self-locked hard gelatin capsules of size ‘1’ imprinted with ‘L 30’ on both cap and body, containing white to off-white pellets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ADULTS APO-Lansoprazole enteric capsules are indicated for: • Healing and long-term management of reflux oesophagitis. • Healing and long-term management for patients with duodenal ulcer. • Healing of benign gastric ulcer. Patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. • Patients with benign peptic lesions that do not respond to H 2 -receptor antagonists. • Eradication of _H. pylori_ from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see section 5.1 PHARMACODYNAMIC PROPERTIES - CLINICAL TRIALS). • Relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. 2 PAEDIATRIC AND ADOLESCENT PATIENTS 1 TO 17 YEARS OF AGE APO-Lansoprazole enteric capsules are indicated for: • Treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. • Healing of erosive oesophagitis. 4.2 DOSE AND METHOD Read the complete document